Quantum BioPharma's Market Manipulation Allegations Featured in CTV W5 Investigative Report

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in the second part of CTV News' investigative program W5's three-part series examining the company's allegations of stock spoofing. The segment, reported by award-winning journalist Jon Woodward, focuses on Quantum BioPharma's $700 million lawsuit against CIBC and RBC and the company's claims of widespread market manipulation affecting its operations.

CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about alleged illegal trading activities during the W5 segment. They noted that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms. The company maintains that these activities have significantly impacted Quantum BioPharma's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment that represents the company's primary research focus.

Quantum BioPharma's lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, making this development potentially significant for the approximately 2.8 million people worldwide living with the condition. The company's allegations suggest that market manipulation activities may have hindered progress on this promising therapeutic candidate.

The company's broader portfolio includes innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma focuses on research and development activities across multiple drug candidates in different stages of development.

Quantum BioPharma also maintains strategic investments through its wholly owned subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additionally, the company retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, along with royalty agreements that could provide significant future revenue streams. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity.

The W5 investigative segment brings increased public attention to allegations of market manipulation within the financial sector, particularly as they relate to biotechnology companies developing potentially life-changing treatments. For investors and industry observers, the case highlights the complex relationship between financial market integrity and biomedical innovation. The outcome of Quantum BioPharma's lawsuit could establish important precedents regarding financial institution accountability and market manipulation enforcement in Canada.

The full press release detailing the W5 coverage is available at https://ibn.fm/t3Tex, while additional news and updates relating to Quantum BioPharma can be found in the company's newsroom at https://ibn.fm/QNTM. The investigative coverage comes as the biotechnology sector continues to face challenges in securing stable funding environments for long-term research and development projects, particularly for conditions like multiple sclerosis that affect millions globally.